Skip to main content

Table 3 Disease-specific survival (DSS) for GIST patients <50 years (sub-cohort I, “young” ) versus ≥50 years (sub-cohort II, “old” ) related to GIST relevant clinicopathological parameters

From: Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST)

Parameter   Disease-specific survival (DSS) rates p-value1
   Sub-cohort I (“young”) Sub-cohort II (“old”)  
n = 87 n = 125
   1 yr 3 yr 5 yr 1 yr 3 yr 5 yr  
Sex male 96.9% 92,3% 92,3% 97,8% 84,8% 78,5% 0.326
  female 100% 100% 100% 94,7% 88,6% 83,2% 0.008
  p-value 2   0.033    0.596   
Localization Gaster 97,2% 97,2% 97,2% 97,0% 88,0% 83,4% 0.036
  Small intestine 100% 93,8% 93,8% 96,4% 88,5% 78,6% 0.267
  p-value 2   0.225    0.813   
Histotype Spindle 100% 97,4% 97,4% 96,4% 90,8% 83,5% 0.028
  epitheliod/mixed 100% 100% 100% 91,7% 66,7% 66,7% 0.061
  p-value 2   0.695    0.097   
Size <1 cm - - - 100,0% 100,0% 85,7% -
  ≥1 cm 100% 97,9% 97,9% 96,6% 87,5% 82,6% 0.012
  p-value 2   -    0.499   
Size <5 cm 96,8% 92,2% 92,2% 100,0% 94,5% 90,9% 0.630
  ≥5 cm 100% 100% 100% 94,1% 83,8% 76,3% 0.008
  p-value 2   0.462    0.012   
Size <10 cm 97,9% 95,0% 95,0% 98,6% 95,3% 93,1% 0.839
  ≥10 cm 100% 100% 100% 92,0% 71,1% 56,0% 0.010
  p-value 2   0.759    <0.001   
Mitotic rate <5 / 50 HPF 100% 100% 100% 98,4% 96,2% 90,4% 0.131
  ≥5 / 50 HPF 100% 100% 100% 91,6% 73,7% 66,7% 0.026
  p-value 2   0.038    0.001   
Mitotic rate <10 / 50 HPF 100% 100% 100% 97,4% 92,4% 88,2% 0.043
  ≥10 / 50 HPF 100% 100% 100% 89,7% 68,6% 56,1% 0.025
  p-value 2   <0.001    <0.001   
Risk (NIH) high 100% 100% 100% 87,9% 68,4% 60,8% 0.004
  non-high 100% 100% 100% 100,0% 98,0% 92,9% 0.227
  p-value   0.027    <0.001   
Risk (AFIP) high 100% 100% 100% 89,4% 70,5% 61,7% 0.018
  non-high 100% 100% 100% 98,5% 94,4% 89,4% 0.084
  p-value   0.013    <0.001   
  1. 1Unadjustedp-values comparing data from study-cohort I vs. II considering DSS after 5 year follow-up.
  2. 2Unadjusted p-values comparing data within study-cohort I and II considering DSS rates after 5 year follow-up.